|Toxiciy Grade:||4||City/State/Province:||San Francisco, CA|
|Treatments:||Biologic therapy||Hospital:||University of California San Francisco|
Patients: This phase III study involved 456 patients with locally advanced prostate cancer. These patients were divided into two similar groups. The median age was 70 in one group and 71 in the other. The men ranged in age from 49 to 88 years old.
Treatment: Patients were treated with goserelin, flutamide and radiation or radiation alone. Goserelin and flutamide are hormone like drugs that deprive the prostate of androgen.
Toxicity: In each group, almost 4% of patients had a grade 3 toxicity related to the radiation therapy. Grade 3 and 4 toxicities were similar in both groups, grade 4 being reported in 1% of patients treated with the drugs and radiation, and 3% in those treated with only radiation. The specific toxicities reported were not provided.
Result: The median overall survival was 8.7 years in patients given both treatments, and 7.3 in those treated with radiation only. This difference did not have statistical significance.
Correspondence: Dr. Mack Roach, III